抗肿瘤治疗心血管损害超声心动图检查专家共识

2020-04-30 中华医学会超声医学分会 超声心动图学组 中华超声影像学杂志.2020,29(4):277-288.

由于肿瘤心脏病学是新兴的学科,各种诊断技术对评估抗肿瘤治疗过程造成的心脏损害均有其优势和不足,许多方法仍需要更多研究验证其价值。目前各种心脏检查技术和方法已应用于抗肿瘤治疗心脏损害的基础和临床研究。超

中文标题:

抗肿瘤治疗心血管损害超声心动图检查专家共识

发布日期:

2020-04-30

简要介绍:

由于肿瘤心脏病学是新兴的学科,各种诊断技术对评估抗肿瘤治疗过程造成的心脏损害均有其优势和不足,许多方法仍需要更多研究验证其价值。目前各种心脏检查技术和方法已应用于抗肿瘤治疗心脏损害的基础和临床研究。超声心动图技术具有易于操作、重复性好、测量指标实用性强等优势,可在抗肿瘤治疗过程中动态随访观察早期心血管损害,为早期心脏保护性治疗提供重要的依据。

为在抗肿瘤治疗过程中应用超声心动图检测指标及早准确发现心脏损害,同时评价心脏保护性治疗疗效,中华医学会超声医学分会和中国医师协会心血管病分会超声心动图专业委员会等联合国内专家撰写了《抗肿瘤治疗心血管损害超声心动图检查专家共识》。本共识针对抗肿瘤治疗常见的心脏损害和已有的证据提出超声心动图检查方法和监测价值,以提高临床医生对肿瘤心脏病学中超声心动图的认识并推动其在临床实践中的应用。

下载附件:

(因为版权问题,不支持下载)

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1180184, encodeId=86c9118018416, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d65631907, createdName=ms9000001438010626, createdTime=Mon Jan 03 21:48:21 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947983, encodeId=a6e194e9837e, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:58:54 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947981, encodeId=6e1794e98146, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:55:29 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901229, encodeId=4ff6901229b4, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Sun Nov 22 17:58:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891896, encodeId=9e4689189681, content=很好的内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/6b3fd3f6582e47f6a929184f4915d467/0dfe8e25dc9444da80ef6d17c14732e3.jpg, createdBy=f4815425641, createdName=ms2000001820580825, createdTime=Tue Oct 13 22:38:48 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2022-01-03 ms9000001438010626

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1180184, encodeId=86c9118018416, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d65631907, createdName=ms9000001438010626, createdTime=Mon Jan 03 21:48:21 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947983, encodeId=a6e194e9837e, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:58:54 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947981, encodeId=6e1794e98146, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:55:29 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901229, encodeId=4ff6901229b4, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Sun Nov 22 17:58:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891896, encodeId=9e4689189681, content=很好的内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/6b3fd3f6582e47f6a929184f4915d467/0dfe8e25dc9444da80ef6d17c14732e3.jpg, createdBy=f4815425641, createdName=ms2000001820580825, createdTime=Tue Oct 13 22:38:48 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2021-03-14 147a22ecm30暂无昵称

    学习一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1180184, encodeId=86c9118018416, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d65631907, createdName=ms9000001438010626, createdTime=Mon Jan 03 21:48:21 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947983, encodeId=a6e194e9837e, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:58:54 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947981, encodeId=6e1794e98146, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:55:29 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901229, encodeId=4ff6901229b4, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Sun Nov 22 17:58:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891896, encodeId=9e4689189681, content=很好的内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/6b3fd3f6582e47f6a929184f4915d467/0dfe8e25dc9444da80ef6d17c14732e3.jpg, createdBy=f4815425641, createdName=ms2000001820580825, createdTime=Tue Oct 13 22:38:48 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2021-03-14 147a22ecm30暂无昵称

    学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1180184, encodeId=86c9118018416, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d65631907, createdName=ms9000001438010626, createdTime=Mon Jan 03 21:48:21 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947983, encodeId=a6e194e9837e, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:58:54 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947981, encodeId=6e1794e98146, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:55:29 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901229, encodeId=4ff6901229b4, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Sun Nov 22 17:58:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891896, encodeId=9e4689189681, content=很好的内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/6b3fd3f6582e47f6a929184f4915d467/0dfe8e25dc9444da80ef6d17c14732e3.jpg, createdBy=f4815425641, createdName=ms2000001820580825, createdTime=Tue Oct 13 22:38:48 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2020-11-22 1480b553m56(暂无昵称)

    学习一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1180184, encodeId=86c9118018416, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63d65631907, createdName=ms9000001438010626, createdTime=Mon Jan 03 21:48:21 CST 2022, time=2022-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947983, encodeId=a6e194e9837e, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:58:54 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947981, encodeId=6e1794e98146, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210817/c8399f5631bf4d12b131e78713e7998c/d7d1a805d7494d49ae2ff8be68d07764.jpg, createdBy=6b985232230, createdName=147a22ecm30暂无昵称, createdTime=Sun Mar 14 01:55:29 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901229, encodeId=4ff6901229b4, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Sun Nov 22 17:58:49 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891896, encodeId=9e4689189681, content=很好的内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201013/6b3fd3f6582e47f6a929184f4915d467/0dfe8e25dc9444da80ef6d17c14732e3.jpg, createdBy=f4815425641, createdName=ms2000001820580825, createdTime=Tue Oct 13 22:38:48 CST 2020, time=2020-10-13, status=1, ipAttribution=)]
    2020-10-13 ms2000001820580825

    很好的内容

    0

拓展阅读

2014 EACVI推荐建议:超声心动图在急性心血管疾病保健中的应用

欧洲协会心血管影像协会(EACVI,European Association of Cardiovascular Imaging) · 2014-11-06

2015 ASE指南:超声心动图作为成人治疗性干预的监测方法

美国超声心动图学会(ASE,American Society of Echocardiography) · 2015-01-20

2015 ACP建议:应用心电图、超声心动图或心肌灌注成像进行心脏检查

美国医师协会(ACP,American College of Physicians) · 2015-03-17

2016 ASE指南:应用超声心动图评估心源性栓塞

美国超声心动图学会(ASE,American Society of Echocardiography) · 2016-01-01

2016 ASE/SCAI建议:利用超声心动图评估左室舒张功能

美国超声心动图学会(ASE,American Society of Echocardiography) · 2016-04-01